Jianjun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianjun Zhu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bing Yan
Kunming children's hospital
1 shared publication - Chenghao Zhanghuang
Department of Urology, Children’s Hospital affiliated to Kunming Medical University (Kunming Children’s Hospital), Kunming, China
1 shared publication - Fengming Ji
Department of Urology, Kunming Children's Hospital (Children's Hospital Affiliated to Kunming Medical University), 288 Qianxing Road, Kunming, Yunnan, 650228, PR China.
1 shared publication - Haoyu Tang
Urology Surgery Department of the Children’s Hospital of Kunminng Medical University, Kunming, People’s Republic of China
1 shared publication - JinRong Li
Urology Surgery Department of the Children’s Hospital of Kunminng Medical University, Kunming, People’s Republic of China
1 shared publication - Yu Hang
Urology Surgery Department of the Children’s Hospital of Kunminng Medical University, Kunming, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 24 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Identification of potential clinical markers associated with prognosis of neuroblastoma
Aim This study retrospectively analyzed the data of patients with neuroblastoma (NB) to explore the risk factors and independent risk factors affecting the prognosis of patients. Method A retrospective analysis was conducted on the data of patients with NB diagnosed and treated at Children’s Hospital of Kunming Medical University from January 2014 to December 2024. Kaplan–Meier (KM) survival analysis and the Cox Proportional Hazards Model were used to ascertain the risk factors and to identify independent risk factors associated with overall survival (OS) and disease-free survival (DFS), respectively. Result A total of 231 patients were retrospectively analyzed. The results of Cox Proportional Hazards Model showed that age, tumor volume of onset (TVO), LNF (lactate dehydrogenase-neuron specific enolase-ferritin), metastasis site, DNA ploidy, and recurrence were independent risk factors affecting the OS. TVO, lactate dehydrogenase (LDH), neuron specific enolase (NSE), ferritin, LNF, image-defined risk factors (IDRFs), metastasis site, and DNA ploidy were independent risk factors affecting the DFS of patients. Conclusion Reliable biomarkers are crucial for effective patient stratification and personalized treatment strategies for NB. Early identification of high-risk patients and the initiation of aggressive treatment can help improve OS and DFS in patients.
- 24 February 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessIdentification of potential clinical markers associated with prognosis of neuroblastoma
Aim This study retrospectively analyzed the data of patients with neuroblastoma (NB) to explore the risk factors and independent risk factors affecting the prognosis of patients. Method A retrospective analysis was conducted on the data of patients with NB diagnosed and treated at Children’s Hospital of Kunming Medical University from January 2014 to December 2024. Kaplan–Meier (KM) survival analysis and the Cox Proportional Hazards Model were used to ascertain the risk factors and to identify independent risk factors associated with overall survival (OS) and disease-free survival (DFS), respectively. Result A total of 231 patients were retrospectively analyzed. The results of Cox Proportional Hazards Model showed that age, tumor volume of onset (TVO), LNF (lactate dehydrogenase-neuron specific enolase-ferritin), metastasis site, DNA ploidy, and recurrence were independent risk factors affecting the OS. TVO, lactate dehydrogenase (LDH), neuron specific enolase (NSE), ferritin, LNF, image-defined risk factors (IDRFs), metastasis site, and DNA ploidy were independent risk factors affecting the DFS of patients. Conclusion Reliable biomarkers are crucial for effective patient stratification and personalized treatment strategies for NB. Early identification of high-risk patients and the initiation of aggressive treatment can help improve OS and DFS in patients.